1. Home
  2. AVLN vs SCSC Comparison

AVLN vs SCSC Comparison

Compare AVLN & SCSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$33.84

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo ScanSource Inc.

SCSC

ScanSource Inc.

HOLD

Current Price

$58.03

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVLN
SCSC
Founded
N/A
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2026
1997

Fundamental Metrics

Financial Performance
Metric
AVLN
SCSC
Price
$33.84
$58.03
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$43.00
AVG Volume (30 Days)
175.5K
288.3K
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.33
EPS
N/A
3.64
Revenue
N/A
$3,846,260,000.00
Revenue This Year
N/A
$2.60
Revenue Next Year
N/A
$4.01
P/E Ratio
N/A
$15.65
Revenue Growth
N/A
7.79
52 Week Low
$24.90
$33.76
52 Week High
$40.17
$66.78

Technical Indicators

Market Signals
Indicator
AVLN
SCSC
Relative Strength Index (RSI) 47.59 48.84
Support Level $34.22 $49.77
Resistance Level $40.08 $59.46
Average True Range (ATR) 1.96 1.98
MACD -0.39 -0.01
Stochastic Oscillator 9.89 32.97

Price Performance

Historical Comparison
AVLN
SCSC

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

About SCSC ScanSource Inc.

ScanSource Inc is a technology distributor uniquely positioned to address complex, converging technologies and to accelerate growth for channel sales partners across hardware, SaaS, connectivity, and cloud. The Company provides technology solutions and services from suppliers of mobility and barcode, POS, payment terminals, physical security, networking, communications, connectivity, and cloud services to channel sales partners located mainly in the United States and Brazil. It has two reportable segments based on the sales model: Specialty Technology Solutions, which generates maximum revenue and includes hardware, SaaS, and subscription services through a wholesale/resale sales model, and Intelisys & Advisory. Geographically, it derives the majority of its revenue from the United States.

Share on Social Networks: